The author discusses the impact of prefilled syringe product contact materials and the filling and stoppering process on protein aggregates.
Wendy Saffell-Clemmer
Advertisement
Wendy Saffell-Clemmer, BPS, is research director, R&D and innovation, at Baxter Healthcare.
Articles by Wendy Saffell-Clemmer
Contract manufacturers must plan for increased analytical resources in development and quality control.
Advertisement
Latest Updated Articles
A Case Study of Developing Analytical MethodsPublished: April 1st 2005 | Updated:
Impact of PFS and Filling Process Selection on Biologic Product StabilityPublished: April 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
